Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
24 août 2020 08h30 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Announces Closing of Offering of Common Stock
21 août 2020 16h05 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Prices Public Offering of Common Stock
19 août 2020 09h10 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
18 août 2020 16h03 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Reports Second Quarter 2020 Financial Results
12 août 2020 16h05 HE
|
Eyenovia, Inc.
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea
11 août 2020 08h00 HE
|
Eyenovia, Inc.
Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commercialization Milestones and Development Costs Arctic Vision to Lead Expansion of Novel...
Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
29 juil. 2020 08h30 HE
|
Eyenovia, Inc.
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
30 juin 2020 16h05 HE
|
Eyenovia, Inc.
NEW YORK, June 30, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format
11 juin 2020 16h10 HE
|
Eyenovia, Inc.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented...
Eyenovia Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format
05 juin 2020 16h10 HE
|
Eyenovia, Inc.
NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...